BRUKINSA Drug Patent Profile

When do Brukinsa patents expire, and when can generic versions of Brukinsa launch?

Brukinsa is a drug marketed by Beone Medicines Usa and is included in two NDAs. There are thirteen patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and seven patent family members in thirty-two countries.

The generic ingredient in BRUKINSA is zanubrutinib. One supplier is listed for this compound. Additional details are available on the zanubrutinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Brukinsa

Brukinsa was eligible for patent challenges on November 14, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 7, 2031. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for BRUKINSA

International Patents:	107
US Patents:	13
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	38
Clinical Trials:	29
Patent Applications:	983
Drug Prices:	Drug price information for BRUKINSA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BRUKINSA
What excipients (inactive ingredients) are in BRUKINSA?	BRUKINSA excipients list
DailyMed Link:	BRUKINSA at DailyMed

See drug prices for BRUKINSA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for BRUKINSA

Constraining patent/regulatory exclusivity:

TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL), AFTER TWO OR MORE LINES OF SYSTEMIC THERAPY

NDA:

213217

Dosage:

CAPSULE;ORAL

NDA:

218785

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for BRUKINSA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Stichting Hemato-Oncologie voor Volwassenen Nederland	Phase 2
Chen Miao	PHASE2
International Extranodal Lymphoma Study Group (IELSG)	Phase 3

See all BRUKINSA clinical trials

Pharmacology for BRUKINSA

Drug Class	Kinase Inhibitor
Mechanism of Action	Bruton's Tyrosine Kinase Inhibitors

Paragraph IV (Patent) Challenges for BRUKINSA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BRUKINSA	Tablets	zanubrutinib	160 mg	218785	1	2025-11-13
BRUKINSA	Capsules	zanubrutinib	80 mg	213217	2	2023-11-14

US Patents and Regulatory Information for BRUKINSA

BRUKINSA is protected by sixty-nine US patents and twelve FDA Regulatory Exclusivities.

This potential generic entry date is based on TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL), AFTER TWO OR MORE LINES OF SYSTEMIC THERAPY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Beone Medicines Usa	BRUKINSA	zanubrutinib	CAPSULE;ORAL	213217-001	Nov 14, 2019		DISCN	Yes	No
Beone Medicines Usa	BRUKINSA	zanubrutinib	CAPSULE;ORAL	213217-001	Nov 14, 2019		DISCN	Yes	No
Beone Medicines Usa	BRUKINSA	zanubrutinib	TABLET;ORAL	218785-001	Jun 10, 2025		RX	Yes	Yes			Y	Y
Beone Medicines Usa	BRUKINSA	zanubrutinib	TABLET;ORAL	218785-001	Jun 10, 2025		RX	Yes	Yes
Beone Medicines Usa	BRUKINSA	zanubrutinib	CAPSULE;ORAL	213217-001	Nov 14, 2019		DISCN	Yes	No			Y
Beone Medicines Usa	BRUKINSA	zanubrutinib	TABLET;ORAL	218785-001	Jun 10, 2025		RX	Yes	Yes

EU/EMA Drug Approvals for BRUKINSA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
BeiGene Ireland Ltd	Brukinsa	zanubrutinib	EMEA/H/C/004978Brukinsa as monotherapy is indicated for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.Brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.Brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL).	Authorised	no	no	no	2021-11-22

International Patents for BRUKINSA

When does loss-of-exclusivity occur for BRUKINSA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

France

Hong Kong

Hungary

Japan

Lithuania

Luxembourg

Mexico

Netherlands

New Zealand

Norway

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering BRUKINSA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2014256633
Brazil	112015025260
Canada	2902686
China	104884458
Cyprus	1118834
Cyprus	2022004

Supplementary Protection Certificates for BRUKINSA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2989106	301161	Netherlands		DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGE OF OWNER(S) NAME
2989106	PA2022504	Lithuania		PRODUCT NAME: ZANUBRUTINIBAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA ; REGISTRATION NO/DATE: EU/1/21/1576 20211121
2989106	LUC00250	Luxembourg		PRODUCT NAME: ZANUBRUTINIB OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/21/1576 20211123
2989106	CA 2022 00008	Denmark		PRODUCT NAME: ZANUBRUTINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/21/1576 20211123
2989106	122022000013	Germany		PRODUCT NAME: ZANUBRUTINIB ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/21/1576 20211122
2989106	2022C/508	Belgium		DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT

BRUKINSA Market Dynamics, Financial Trajectory, Patent Exclusivity, and Competitive Outlook

Last updated: August 2, 2026

BRUKINSA, the zanubrutinib-based Bruton tyrosine kinase inhibitor marketed by BeiGene, has become one of the fastest-growing targeted therapies in B-cell malignancies. Global product revenue reached approximately $1.5 billion in 2024, up from about $1.0 billion in 2023 and $564 million in 2022. Growth is driven by chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenström macroglobulinemia, mantle cell lymphoma, and marginal zone lymphoma.

The commercial thesis depends on four factors: continued share gains against IMBRUVICA and CALQUENCE, expansion across hematologic indications, international reimbursement, and protection from generic entry through at least the early 2030s and potentially into 2034 for core U.S. patent claims.

What is BRUKINSA and how does zanubrutinib compete in BTK inhibitors?

BRUKINSA is an oral, covalent BTK inhibitor. It binds irreversibly to Bruton tyrosine kinase and blocks B-cell receptor signaling involved in the growth and survival of malignant B cells.

Product	Active ingredient	Company	Principal commercial indications
BRUKINSA	Zanubrutinib	BeiGene	CLL/SLL, WM, MCL, MZL
IMBRUVICA	Ibrutinib	AbbVie and Janssen	CLL/SLL, WM, MCL, marginal-zone and other B-cell malignancies
CALQUENCE	Acalabrutinib	AstraZeneca	CLL/SLL, MCL
JAYPIRCA	Pirtobrutinib	Eli Lilly	Previously treated mantle cell lymphoma and CLL/SLL settings
VONJO	Pacritinib	CTI BioPharma, acquired by Sobi	Myelofibrosis, not a direct BTK competitor

BRUKINSA competes primarily on efficacy, selectivity, dosing flexibility, and safety. Unlike first-generation IMBRUVICA, zanubrutinib was designed as a more selective BTK inhibitor, with lower off-target activity against kinases associated with atrial fibrillation, hypertension, and bleeding.

What FDA approvals does BRUKINSA have?

The FDA initially approved BRUKINSA in November 2019 under the accelerated approval pathway for adult patients with mantle cell lymphoma who had received at least one prior therapy. The FDA later converted the MCL approval to regular approval after confirmatory clinical data.

Date	FDA milestone	Indication or regulatory event
November 2019	First U.S. approval	Adult patients with mantle cell lymphoma after at least one prior therapy
November 2019	Approval	Waldenström macroglobulinemia
September 2021	Approval	Relapsed or refractory marginal zone lymphoma after at least one anti-CD20-containing regimen
January 2023	Approval	Adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
2023-2024	Label expansion and global filings	Continued international expansion across B-cell malignancies

The CLL/SLL approval materially expanded the addressable market because CLL is a larger and more durable treatment market than relapsed MCL. CLL also supports long-term treatment duration, which increases revenue per treated patient.

The FDA label includes warnings for hemorrhage, infections, cytopenias, cardiac arrhythmias, second primary malignancies, and embryo-fetal toxicity. These risks are relevant to physician selection and payer management but have not prevented rapid adoption.

Sources: U.S. Food and Drug Administration, 2019, 2021, 2023; BeiGene, 2024.

How large is the BRUKINSA market opportunity?

BRUKINSA addresses several B-cell malignancies with different treatment durations and competitive conditions.

Chronic lymphocytic leukemia and small lymphocytic lymphoma

CLL/SLL is the largest commercial opportunity. Treatment can continue for years, especially when patients receive a continuous BTK inhibitor rather than a fixed-duration venetoclax-based regimen.

BRUKINSA competes against:

• IMBRUVICA, which has a large installed base and extensive physician familiarity.
• CALQUENCE, a second-generation BTK inhibitor with strong CLL adoption.
• VENCLEXTA-based regimens, which offer fixed-duration treatment in some settings.
• JAYPIRCA, which targets patients with prior covalent BTK inhibitor exposure.

The CLL market is shifting toward second-generation BTK inhibitors because of tolerability and cardiovascular considerations. BRUKINSA’s opportunity is strongest where clinicians prioritize treatment continuity, response depth, and lower rates of atrial fibrillation relative to ibrutinib.

Waldenström macroglobulinemia

BRUKINSA has an important position in WM, where the disease is chronic and treatment frequently requires repeated or extended therapy. The ASPEN study supported zanubrutinib’s use against ibrutinib, particularly on atrial fibrillation and certain tolerability measures. WM is smaller than CLL but has strong treatment persistence.

Mantle cell lymphoma

MCL provided BRUKINSA with its first FDA indication. The market is commercially valuable but more exposed to treatment sequencing, cellular therapies, bispecific antibodies, and pirtobrutinib.

Generic and competitive pressure is higher in later-line MCL than in frontline CLL because multiple targeted and cellular therapies are entering the treatment pathway.

Marginal zone lymphoma

MZL is a smaller indication, but the approval increases treatment breadth and improves sales-force efficiency. Its contribution is incremental rather than transformational.

How fast are BRUKINSA sales growing?

BRUKINSA has moved from a regional oncology product to a global commercial asset.

Fiscal year	BRUKINSA revenue	Approximate year-over-year growth
2022	$564 million	More than 100%
2023	$1.03 billion	Approximately 82%
2024	Approximately $1.5 billion	Approximately 45%-50%

BeiGene reported that BRUKINSA growth came from higher demand in the United States, European launches, broader reimbursement, and increased use in CLL/SLL. The company’s overall product revenue also expanded sharply as BRUKINSA became its central commercial product. [1][2]

The growth profile is changing. Early sales growth reflected new-country launches and initial indication expansion. Future growth depends more on market share conversion, treatment duration, frontline use, and pricing discipline.

Revenue concentration

BRUKINSA has become a major concentration point in BeiGene’s portfolio. The company historically commercialized several oncology products, including REVLIMID in China under a licensing arrangement, but BRUKINSA now represents the core global growth engine.

This concentration increases operating leverage when prescriptions rise. It also increases exposure to:

• BTK inhibitor competition.
• U.S. payer restrictions.
• China pricing and volume-based procurement policies.
• Patent challenges.
• Safety findings that could alter treatment sequencing.
• Slower-than-expected international reimbursement.

What is driving BRUKINSA’s commercial growth?

U.S. market share gains

The United States is the most important market for BRUKINSA. The product is taking share from IMBRUVICA and competing directly with CALQUENCE in CLL/SLL.

Commercial adoption is supported by:

• FDA approval across four B-cell malignancies.
• Use in frontline and relapsed settings.
• A selective BTK profile.
• Favorable clinical comparisons with ibrutinib in WM and MCL.
• Physician demand for alternatives to ibrutinib.
• Expanded payer coverage following the CLL/SLL approval.

International expansion

BeiGene has used direct commercialization in selected markets and distribution or regional partnerships elsewhere. BRUKINSA has received approvals in multiple jurisdictions, including Europe, Canada, Australia, Japan, and other Asian markets.

International revenue generally develops more slowly than U.S. revenue because reimbursement decisions, health technology assessments, and tender systems delay broad access. The upside is longer product runway in countries where BTK inhibitor penetration remains lower.

Treatment duration

Continuous oral therapy creates recurring revenue. This differs from fixed-duration regimens, where the manufacturer receives fewer treatment months per patient but may benefit from a larger eligible population.

Duration is affected by:

• Disease response.
• Adverse events.
• Physician preference.
• Sequencing with venetoclax.
• Use of CAR-T, bispecific antibodies, or pirtobrutinib after progression.
• Payer utilization controls.

What patents protect BRUKINSA and when does it lose exclusivity?

BRUKINSA is protected by a combination of compound, formulation, dosing, and method-of-use patent families. Public U.S. patent records identify core zanubrutinib patent protection extending into the 2030s. One important U.S. patent family associated with zanubrutinib compounds and therapeutic use is U.S. Patent No. 10,570,197, with a stated expiration in 2034 before any applicable patent-term adjustment or extension.

The commercial exclusivity picture is broader than a single patent.

Protection category	Strategic role
Core compound claims	Protect zanubrutinib and related chemical structures
Salt, crystal, and formulation claims	Can restrict alternative dosage forms or manufacturing approaches
Method-of-treatment claims	Cover use in CLL/SLL, WM, MCL, MZL, and other B-cell diseases
Dosing-regimen claims	Can protect specific dosing schedules or patient populations
Regulatory exclusivity	Provides separate protection from patents for approved indications

The practical U.S. generic-entry date depends on the patents listed in the FDA Orange Book, patent-term adjustment, pediatric exclusivity, litigation outcomes, and any settlement with an ANDA applicant. A core patent expiration around 2034 would normally make pre-2034 generic entry difficult unless a challenger invalidates the patent or wins a non-infringement judgment.

What is the Orange Book status of BRUKINSA?

BRUKINSA is a small-molecule prescription drug subject to the FDA’s abbreviated new drug application framework. It is not a biologic and therefore does not use the biosimilar pathway.

Orange Book-listed patents are commercially important because an ANDA applicant must address them through:

• Paragraph I certification, if no patent information is listed.
• Paragraph II certification, if the patent has expired.
• Paragraph III certification, if the applicant will wait for patent expiration.
• Paragraph IV certification, if the applicant asserts that the patent is invalid, unenforceable, or will not be infringed.

A paragraph IV filing can trigger a 30-month stay of FDA approval if the patent holder brings an infringement action within the statutory period under the Hatch-Waxman Act.

The relevant diligence question is not simply whether BRUKINSA has a 2034 patent. It is whether every listed patent blocking the proposed generic product can be overcome. A generic developer may challenge composition claims, formulation claims, or methods of use separately.

Which companies are challenging BRUKINSA patents?

Publicly documented commercial competition is more visible than reported U.S. paragraph IV litigation. The most significant near-term challenge comes from competing branded BTK inhibitors rather than generic manufacturers.

Key competitors include:

• AstraZeneca’s CALQUENCE, which is a direct second-generation BTK competitor.
• AbbVie and Janssen’s IMBRUVICA, which retains a substantial installed base.
• Eli Lilly’s JAYPIRCA, which targets patients whose disease has progressed after covalent BTK therapy.
• Fixed-duration venetoclax combinations.
• Cellular therapies and bispecific antibodies in later-line disease.

No biosimilar company can directly challenge BRUKINSA because zanubrutinib is a chemically synthesized small molecule. The relevant future challenge is an ANDA-based generic challenge.

What formulation patents and manufacturing barriers protect BRUKINSA?

The main technical barriers are chemical synthesis, solid-state form, impurity control, analytical characterization, and reproducible oral dosage manufacturing.

A generic applicant may be able to design around a particular formulation claim while still needing to demonstrate pharmaceutical equivalence and bioequivalence. Manufacturing complexity alone does not prevent generic entry, but it can delay development and raise the cost of a successful ANDA.

Potentially relevant intellectual-property categories include:

• Zanubrutinib polymorphs and crystalline forms.
• Capsule composition.
• Stability and storage conditions.
• Process intermediates.
• Purification methods.
• Impurity specifications.
• Scale-up processes.
• Manufacturing know-how not disclosed in issued patent claims.

BeiGene’s global manufacturing and supply network is commercially important, but manufacturing capacity is not the same as patent protection. The stronger barriers are enforceable composition and use claims combined with regulatory and clinical-development requirements.

How does the BRUKINSA patent estate compare with CALQUENCE and IMBRUVICA?

Factor	BRUKINSA	CALQUENCE	IMBRUVICA
Generation	Second-generation covalent BTK inhibitor	Second-generation covalent BTK inhibitor	First-generation covalent BTK inhibitor
Main commercial strength	Rapid share growth and broadening labels	Strong CLL position and tolerability profile	Installed base and extensive indications
U.S. launch	2019	2017	2013
Generic exposure	Later-stage risk, with core protection into the 2030s	Patent and regulatory protection extending into the 2030s for key claims	Earlier and more complex patent litigation history
Biosimilar risk	None	None	None
Main competitive vulnerability	Dependence on continued share conversion	Competition from BRUKINSA and other next-generation agents	Safety perception and newer BTK alternatives

IMBRUVICA has the deepest commercial history but faces the greatest age-related erosion risk. CALQUENCE has a stronger early-mover position in CLL. BRUKINSA has the fastest growth trajectory and a broad label, but it must sustain differentiation in a crowded class.

What patent litigation affects BRUKINSA and are there settlement agreements?

The principal legal risk is future Hatch-Waxman litigation involving ANDA applicants. A paragraph IV notice could produce district-court litigation over composition, formulation, or method-of-use patents.

Potential litigation outcomes include:

1. Settlement with a licensed generic launch date.
2. Judgment upholding the patent until expiration.
3. Invalidity or non-infringement ruling.
4. Partial launch limited by carved-out indications.
5. At-risk launch before final resolution.

A settlement could create a defined generic entry date materially earlier than the nominal 2034 patent expiration. No widely reported settlement should be assumed without a current court docket, SEC filing, or FDA patent record confirming it.

When does BRUKINSA lose exclusivity?

BRUKINSA’s market exclusivity will end in stages rather than on one date.

Regulatory exclusivity

The original U.S. approval received orphan-drug exclusivity for certain indications. Orphan exclusivity blocks approval of the same drug for the same orphan indication for seven years, subject to statutory exceptions. The earliest 2019 orphan-related periods have already expired or are no longer the primary commercial barrier.

The CLL/SLL approval in 2023 created a newer regulatory foothold, but regulatory exclusivity is indication-specific and does not necessarily prevent a generic from entering for other approved uses if patent protections are avoided.

Patent exclusivity

Core patent protection appears to be the more important barrier. Publicly identified U.S. patent protection reaches into the 2030s, with certain core claims associated with expiration around 2034. Actual entry timing may change through patent-term adjustments, patent-term extension, pediatric exclusivity, litigation, or settlement.

Likely launch scenarios

Scenario	Indicative timing	Commercial effect
No successful early challenge	Around core patent expiration	Abrupt price and volume pressure after generic approval
Settlement with licensed entry	Before core expiration	Gradual erosion, often with restricted initial access
Successful invalidity challenge	Before core expiration	Potential rapid multi-generic entry
Carved-out indication launch	Before full patent expiry	Limited revenue erosion in non-protected uses

What generic entry risks exist for BRUKINSA?

The near-term generic risk is low relative to the risk of branded competition. The larger threats through the remainder of the decade are:

• CALQUENCE share retention in CLL.
• JAYPIRCA use after BTK resistance.
• Fixed-duration venetoclax regimens.
• Payer pressure on oral oncology pricing.
• Treatment migration to cellular and bispecific therapies.
• Lower international net prices.
• Safety differentiation becoming less meaningful as the class matures.

The generic risk rises sharply when a credible ANDA applicant files a paragraph IV certification and the patent holder’s response becomes public. Until then, commercial erosion is more likely to come from competing products than from substitution with low-cost generic zanubrutinib.

How strong is the BRUKINSA commercial and patent estate?

BRUKINSA has a strong commercial position but a more concentrated risk profile than diversified oncology portfolios.

Strengths

• Rapid revenue growth.
• Broad FDA indication base.
• Large CLL/SLL opportunity.
• Recurring revenue from continuous treatment.
• Second-generation BTK selectivity.
• Global launch infrastructure.
• Core patent protection extending into the 2030s.

Risks

• Heavy dependence on one leading product.
• Direct competition from CALQUENCE.
• Mature-class pricing pressure.
• Later-line disruption from pirtobrutinib.
• Patent litigation exposure as sales scale.
• Reimbursement delays outside the United States.
• Potential safety findings associated with long-term BTK inhibition.

The estate is commercially strong because product adoption is occurring well before expected core patent expiry. That creates time to build treatment persistence, physician familiarity, and international market share. The main valuation question is whether BRUKINSA can maintain premium positioning after the BTK class becomes more crowded.

What is the BRUKINSA revenue outlook?

A reasonable base case is continued double-digit growth through the second half of the 2020s, with a gradual slowdown as the U.S. CLL market matures and CALQUENCE strengthens.

Revenue should be supported by:

• Frontline CLL/SLL penetration.
• Higher treatment duration.
• Expansion in Europe and Asia.
• Use in WM and MZL.
• Conversion from ibrutinib.
• Increased recognition of cardiovascular tolerability differences.

Revenue could underperform if:

• CALQUENCE captures most new CLL starts.
• Payers impose step edits.
• Fixed-duration regimens gain share.
• JAYPIRCA and other agents reduce post-BTK treatment duration.
• International reimbursement lowers net pricing.
• Patent litigation accelerates generic entry.

The 2022-to-2024 trajectory shows product-market acceptance, not merely a one-time launch effect. The next phase will test whether BeiGene can convert growth into durable profitability while funding international commercialization and clinical development.

Key Takeaways

• BRUKINSA is BeiGene’s primary global growth product and generated approximately $1.5 billion in 2024 revenue.
• The largest opportunity is CLL/SLL, where continuous treatment supports recurring revenue.
• BRUKINSA competes directly with IMBRUVICA and CALQUENCE and indirectly with venetoclax combinations, JAYPIRCA, cellular therapies, and bispecific antibodies.
• It is a small-molecule drug, so biosimilar competition does not apply.
• Core U.S. patent protection reaches into the 2030s, with public records associating important zanubrutinib claims with expiration around 2034.
• The most material near-term risk is branded competition, not generic substitution.
• Future generic entry will depend on Orange Book listings, paragraph IV filings, patent litigation, and any settlement-based launch date.
• BeiGene’s revenue trajectory remains attractive but increasingly depends on market-share conversion and sustained differentiation in a crowded BTK class.

FAQs About BRUKINSA Market and Patent Exclusivity

Is BRUKINSA expected to face generic competition before 2030?

No major generic threat should be assumed before 2030 absent a successful paragraph IV challenge, a patent invalidity ruling, or an early-entry settlement.

Does BRUKINSA have orphan-drug exclusivity?

Yes. Certain BRUKINSA indications received orphan-drug exclusivity, but the most important long-term barrier is patent protection rather than the earliest orphan exclusivity periods.

Is zanubrutinib a biologic or a small-molecule drug?

Zanubrutinib is an orally administered small-molecule drug. Future competitors would file ANDAs rather than biosimilar applications.

Which disease contributes most to BRUKINSA growth?

CLL/SLL is the largest growth opportunity because it has a larger patient population and often involves prolonged continuous treatment.

Could CALQUENCE overtake BRUKINSA?

CALQUENCE remains a material threat in CLL, but BRUKINSA’s broad label, global expansion, and rapid U.S. share gains support continued competitive momentum. The outcome depends on comparative safety perception, physician preference, payer access, and treatment sequencing.

References

1. BeiGene, Ltd. (2024). Annual report for the year ended December 31, 2023.
2. BeiGene, Ltd. (2025). Annual report for the year ended December 31, 2024.
3. U.S. Food and Drug Administration. (2019). FDA approves zanubrutinib for mantle cell lymphoma.
4. U.S. Food and Drug Administration. (2019). BRUKINSA prescribing information.
5. U.S. Food and Drug Administration. (2021). FDA grants accelerated approval to zanubrutinib for marginal zone lymphoma.
6. U.S. Food and Drug Administration. (2023). FDA grants regular approval to zanubrutinib for chronic lymphocytic leukemia or small lymphocytic lymphoma.
7. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
8. U.S. Patent and Trademark Office. (2020). U.S. Patent No. 10,570,197: Compounds and methods for treating cancer.
9. Tam, C. S., Opat, S., D'Sa, S., Jurczak, W., Lee, H. P., Cull, G., et al. (2020). A randomized phase 3 trial of zanubrutinib versus ibrutinib in symptomatic Waldenström macroglobulinemia. Blood, 136(18), 2038-2050.

DrugChatter Q&A for BRUKINSA

When does the patent run out on brukinsa?
Now that brukinsa is in tablet form will tje price go down?
Manufacturing process of brukinsa capsules?
Does brukinsa needs premeds?
How much does brukinsa cost?